Hemostasis in COVID-19: an Adaptive Clinical Trial
Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
Hypercoagulability has been demonstrated in COVID-19, leading to respiratory distress and
increased mortality. This is an adaptive clinical trial to compare the efficacy and safety of
two experimental strategies in patients with COVID-19: ASA or inhaled UFH associated with
standard VTE prophylaxis.